Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion
Imam Waked(Menoufia University), Philip J. Johnson(Prince of Wales Hospital), Paul B.S. Lai(Chinese University of Hong Kong), Daniel H. Palmer(University of Liverpool), Hidenori Toyoda(Ogaki Municipal Hospital), Takashi Kumada(Gifu Kyoritsu University), Mercedes Iñarrairaegui(University of Cambridge), Stephen L. Chan(Chinese University of Hong Kong), Dominik Bettinger(University Medical Center Freiburg), Martha M. Kirstein(University of Lübeck), Tim Meyer(The Royal Free Hospital), Asmaa Gomaa(Menoufia University), Toshifumi Tada(Himeji Red Cross Hospital), Arndt Vogel(Princess Margaret Cancer Centre), Bruno Sangro(Clinica Universidad de Navarra), Sarah Berhane(University Hospitals Birmingham NHS Foundation Trust), Frankie Mo(Chinese University of Hong Kong), Nicholas Stern(University of Liverpool), Winnie Yeo(Chinese University of Hong Kong)
Cited by 90
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k